ストックスクリーナーアプリを入手
2.42
0.41%
0.010
プレマーケット:
2.41
-0.010
-0.41%
Cellectar Biosciences Inc (CLRB) 最新ニュース
Cellectar Biosciences Inc (CLRB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cellectar Biosciences Inc (CLRB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CLRB|Cellectar Biosciences Inc|Price:2.410|Chg%:-0.060 - TradingKey
Cellectar Biosciences Inc (CLRB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Cellectar Biosciences Inc (CLRB) Balance Sheet - TradingKey
Cellectar Biosciences Inc (CLRB) Cash Flow - TradingKey
CLRB Stock Surged 27% Today – Here’s Why Retail Is Bullish About Cellectar’s Blood Cancer Trial Data - Stocktwits
Cellectar Biosciences (CLRB) Q1 2026 earnings summary - Quartr
Cellectar Biosciences (CLRB) Proxy filing Summary - Quartr
Cellectar Biosciences (CLRB) Q4 2025 earnings summary - Quartr
Cellectar Biosciences (CLRB) Registration filing Summary - Quartr
Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate radiotherapy pipeline, led by iopofosine I-131 in Waldenstrom macroglobulinemia - Bitget
Cellectar Publishes Phase 1 Iopofosine Data - t.co
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers - Sahm
Cellectar publishes phase 1 data on multiple myeloma treatment By Investing.com - Investing.com South Africa
Cellectar Biosciences (CLRB) Announces Positive Phase 1 Study Re - GuruFocus
Cellectar publishes phase 1 data on multiple myeloma treatment - Investing.com
Cellectar Biosciences Announces Publication of Phase 1 Data for Iopofosine I 131 in Relapsed/Refractory Multiple Myeloma - Quiver Quantitative
Cellectar Myeloma Data: 84.6% of 26 Evaluable Patients Stable or Better - Stock Titan
Brookline Capital Initiates Cellectar BioSciences(CLRB.US) With Buy Rating, Announces Target Price $15 - Moomoo
Cellectar Biosciences (CLRB) Stock Fair Value Moves Lower As Analysts Weigh Execution Risk - Yahoo Finance
Form 4 Cellectar Biosciences Inc For: 10 July By Investing.com - Investing.com Nigeria
Form 4 Cellectar Biosciences Inc For: 10 July - Investing.com India
Cellectar Biosciences, Inc. Files Form 8-K: Updated Stock Incentive Plan and Corporate Details for 2026 - Minichart
Cellectar Biosciences (NASDAQ: CLRB) awards 15,000 stock options to consultant - Stock Titan
Cellectar Biosciences (NASDAQ: CLRB) holders approve more stock awards and large warrant exercise - Stock Titan
Form 4 Cellectar Biosciences Inc For: 8 July By Investing.com - Investing.com Nigeria
Cellectar Biosciences (CLRB) CEO awarded 250,000 stock options - Stock Titan
Cellectar (CLRB) awards director Andrew Gu 25,000 options - Stock Titan
Consultant for Cellectar (NASDAQ: CLRB) receives grant of 15,000 stock options - Stock Titan
Cellectar Biosciences (CLRB) Edges Lower Amid Support Test; Resistance Holds as Range TightensMcClellan Summation - dars.gov.et
CLRBCellectar Biosciences Inc Options - Finviz
Price to book forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
Enterprise value to EBIT forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
Price to earnings forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
Enterprise value to EBITDA forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
Cellectar Biosciences, Inc. Actuals & Estimates (NASDAQ:CLRB) - TradingView
Enterprise value to revenue forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
CLRB Forecast — Price Target — Prediction for 2027 - TradingView
Cellectar Biosciences (CLRB) Surges 12.5%: Key Levels and Technical OutlookRevenue Growth Stocks - dars.gov.et
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Cellectar Biosciences Inc (CLRB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cellectar Biosciences Inc (CLRB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cellectar Biosciences Inc (CLRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cellectar Biosciences Inc (CLRB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cellectar Biosciences Inc (CLRB) Institutional Confidence - TradingKey
Cellectar Biosciences (CLRB) Edges Higher: Consolidation Near Key ResistanceFund Manager Survey - newsline.com
Cellectar Biosciences Inc (CLRB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cellectar Biosciences (CLRB) Slides 4.27% as Support Test LoomsInstitutional Flow Picks - dars.gov.et
Number of shareholders of Cellectar Biosciences, Inc. – MUN:NV40 - TradingView
Cellectar Biosciences (CLRB) director Andrew Gu submits initial Form 3 ownership filing - Stock Titan
Cellectar Biosciences (CLRB) Declines 3.09% as Stock Tests Support Near $2.38Swing Entry Signals - newsline.com
Janus Henderson Group holds 9.99% of Cellectar Biosciences (CLRB) - Stock Titan
Cellectar Biosciences (CLRB) Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress ContinuesProfit Announcement - newsline.com
[EFFECT] Cellectar Biosciences, Inc. SEC Filing - Stock Titan
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):